Jim Simons Tango Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$7.51 - $12.88 $416,054 - $713,552	-55,400 Reduced 45.79%	65,600 $521,000
Q4 2023 Feb 13, 2024	BUY	$6.52 - $12.01 $539,856 - $994,428	82,800 Added 216.75%	121,000 $1.2 Million
Q3 2023 Nov 14, 2023	SELL	$2.93 - $11.26 $118,665 - $456,030	-40,500 Reduced 51.46%	38,200 $430,000
Q2 2023 Aug 11, 2023	BUY	$2.67 - $4.7 $47,526 - $83,660	17,800 Added 29.23%	78,700 $261,000
Q1 2023 May 12, 2023	BUY	$3.76 - $8.06 $133,856 - $286,936	35,600 Added 140.71%	60,900 $241,000
Q4 2022 Feb 13, 2023	BUY	$3.41 - $8.29 $48,081 - $116,888	14,100 Added 125.89%	25,300 $183,000
Q3 2022 Nov 14, 2022	BUY	$3.25 - $5.46 $36,400 - $61,152	11,200 New	11,200 $41,000

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $268M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.